Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCapital BlueCross Value Plus Formulary Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCapital BlueCrossPolicy N/A

    Value Plus Formulary — Prescription Drug Coverage and Utilization Management

    Customize your policy alerts

    Sign up for all Capital Bluecross policy alerts

    Know when Capital Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs coverage, utilization management, and pharmacy benefit administration for Capital BlueCross Value Plus formulary members, including prior authorization, step therapy, quantity limits, specialty drug distribution, and nonformulary exception processes. Affects providers, pharmacists, and members covered under Capital BlueCross prescription drug plans.

    Policy Summary
    PayerCapital BlueCross
    PolicyValue Plus Formulary — Prescription Drug Coverage and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization or formulary exception requests on behalf of the member when the formulary indicates a Prior Authorization or nonformulary status.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30-daystandard supply limit for specialty drugs
    Accredodesignated specialty pharmacy provider
    PA / ST / QLLutilization management tools used
    20+distinct drug entries shown (segments)
    NCapplicable states

    Coverage rules and exclusions

    Coverage rules

    Covered when the following general conditions and utilization management requirements are met:

    General coverage: Drug must be FDA-approved (NDA, ANDA, or BLA) unless superseded by legal or group-specific benefits; coverage is subject to the member's Benefits Booklet (Certificate of Coverage) and medical necessity determinations.FDA approval

    Providers may submit a nonformulary exception if medical necessity precedes P&T review.

    Utilization management: When indicated in the formulary, Prior Authorization, Step Therapy, and Quantity Level Limits apply; required approvals must be obtained before coverage or claims may be denied and the member may be financially responsible.PA/ST/QLL as indicated

    Formulary uses a dot in the corresponding column to indicate commonly required PA, ST, or QLL.

    Policy Summary
    PayerCapital BlueCross
    PolicyValue Plus Formulary — Prescription Drug Coverage and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization or formulary exception requests on behalf of the member when the formulary indicates a Prior Authorization or nonformulary status.
    SourceLink
    On This Page
    Coverage rules and exclusionsFormulary drug listings and sample entriesPrior authorization, step therapy, quantity limits, and submission instructionsDefinitions and policy backgroundStep therapy applicabilityQuantity level limits and related flagsSpecialty pharmacy and site of service rules
    Nonformulary / exceptions: Drugs not listed on the formulary are not covered unless an approved nonformulary consideration (formulary exception) request is submitted by the provider on behalf of the member.Approved exception

    Provider must submit the nonformulary consideration request per plan processes.

    Contractual exclusions and limitations: Coverage excludes items listed in member benefit documents (examples include appetite suppressants/weight loss drugs, anti-obesity agents such as semaglutide products, cosmetic indications, erectile dysfunction drugs, non-self-administered injectables, experimental/investigational or off-label uses, some vitamins, and OTC-equivalent products).Plan-specific benefit booklet

    Some employers may purchase additional coverage or exclude classes; verify the member's Benefit Booklet.

    Examples of contractual exclusions include: appetite suppressants / weight-loss drugs, anti-obesity agents (for example, Wegovy), drugs used for cosmetic purposes (e.g., wrinkle or hair‑loss treatments), erectile dysfunction drugs, non-self‑administered injectable drugs, certain vitamins (non‑prenatal), and products with OTC equivalents. Coverage for these categories can vary by employer-selected plan; members should consult their Benefits Booklet (Certificate of Coverage) for plan‑specific exclusions.

    Prescription drugs that are not listed on the formulary are not covered by the plan unless an approved nonformulary (formulary exception) request is obtained. The provider must submit a nonformulary consideration (formulary exception) request on the member’s behalf to seek coverage for a non‑formulary product.

    The provided formulary extract contains administrative flags (Tier, Specialty, Prior Authorization, Step Therapy, Quantity Level Limits, PHC, Limited Distribution) for many products, but these chunks do not include any separate or explicit "medical necessity" exclusion list. In other words, no discrete medical‑necessity exclusions are documented in these sections — the content is limited to formulary entries and administrative indicators.

    Drugs that are not FDA‑approved and uses described as experimental or investigational (including off‑label) are not covered under the prescription drug benefit.

    Formulary drug listings and sample entries

    Formulary — grouped sample (antivirals & specialty)mixedCovered
    PEGASYSPEGASYS - peginterferon alfa-2a inj 180 mcg/ml (also listed as PEGASYS prefilled syr / soln - peginterferon alfa-2a)
    PEGASYS prefilled syrPEGASYS - peginterferon alfa-2a soln prefilled syr 180 mcg/0.5ml
    PREZCOBIXPREZCOBIX - darunavir-cobicistat tab 675-150 mg, 800-150 mg (darunavir formulations)
    PREZISTAPREZISTA - darunavir oral susp 100 mg/ml; PREZISTA - darunavir tab 75 mg, 150 mg (darunavir formulations)
    Formulary — drug entries (sample)mixedCovered
    PEGASYSPEGASYS - peginterferon alfa-2a inj 180 mcg/ml (listed; prior authorization and limited distribution flags present in source)
    PEGASYS prefilled syrPEGASYS - peginterferon alfa-2a soln prefilled syr 180 mcg/0.5ml (listed separately in source)
    PREZCOBIXPREZCOBIX - darunavir-cobicistat tab 675-150 mg, 800-150 mg (listed; darunavir fixed-dose with cobicistat)
    PREZISTA oral susp/tabPREZISTA - darunavir oral susp 100 mg/ml; darunavir tablets 75 mg, 150 mg (oral suspension and tablet formulations included)
    Formulary — larger sample block (antiretrovirals and related)mixedCovered
    PREZCOBIXPREZCOBIX - darunavir-cobicistat tab 675-150 mg, 800-150 mg (darunavir formulations consolidated)
    PREZISTAPREZISTA - darunavir oral susp 100 mg/ml; PREZISTA - darunavir tab 75 mg, 150 mg (suspension and tablet strengths)
    PEGASYSPEGASYS - peginterferon alfa-2a inj 180 mcg/ml; PEGASYS prefilled syr 180 mcg/0.5ml (both vial/injection and prefilled syringe presentations included)
    Formulary — product strengths mentionedmixed
    PEGASYS_strength180 mcg/ml inj; 180 mcg/0.5ml prefilled syringe
    PREZCOBIX_strengthdarunavir-cobicistat 675-150 mg; 800-150 mg
    PREZISTA_strengthdarunavir oral suspension 100 mg/ml; tablets 75 mg, 150 mg
    Formulary — combination product strengthsmixed
    PREZCOBIX_combodarunavir-cobicistat 675-150 mg, 800-150 mg
    PEGASYS_presentationpeginterferon alfa-2a inj 180 mcg/ml; prefilled syr 180 mcg/0.5ml
    Formulary — grouped entries (identifiers & limited distribution)mixedCovered
    PEGASYS_limitedPEGASYS entries in source include Limited Distribution and Prior Authorization flags
    PREZCOBIX_limitedPREZCOBIX listed with tier BP and standard formulary attributes in source
    PREZISTA_limitedPREZISTA listed with oral suspension and tablet forms; source shows standard formulary attributes
    Hormonal contraceptives and other grouped examples (context)mixed
    Context_REF1Section contains many grouped drug listing examples; PEGASYS and PREZCOBIX/PREZISTA consolidated into antiviral group for clarity

    Prior authorization, step therapy, quantity limits, and submission instructions

    Prior Authorization

    Prior authorization requirement

    Prior Authorization (PA): Certain drugs listed in the formulary require prior authorization. When a PA indicator (•) is shown in the Prior Authorization column next to a drug, the provider must submit a PA request and obtain approval before the drug will be covered. Claims for flagged products may be denied if an approved PA is not on file. Limited distribution products may also be flagged and require special handling for fulfillment.

    • PA indicated on the drug list by a dot (•) in the Prior Authorization column
    • Claims for PA‑flagged drugs can be denied without an approved PA
    • Limited Distribution status may affect where the drug can be dispensed
    Documentation Required

    Prior authorization indicated on drug list

    Providers must follow the PA process for drugs marked on the formulary. The formulary table includes columns showing administrative attributes (Tier, Specialty, Prior Authorization, Step Therapy, Quantity Level Limits, PHC, Limited Distribution). If a drug shows the PA indicator, submit a prior authorization request using the payer's PA form or electronic submission channel.

    • Required formulary fields include: Drug Name, Tier, Specialty, Prior Authorization, Step Therapy, Quantity Level Limits, PHC, Limited Distribution
    • Formulary table fields are present for each product to document UM attributes and fulfillment constraints
    • Providers may submit PA or nonformulary exception requests on behalf of members
    Prior Authorization

    Prior Authorization requirement — examples

    Examples of products marked requiring PA include specialty antivirals and selected oncology agents. The formulary shows many drug‑level examples (e.g., tobramycin nebulizer solutions, some HIV agents, hepatitis C direct‑acting antivirals, targeted oncology agents) with PA and/or Limited Distribution flags.

    • Antivirals with PA flags: tobramycin nebu soln (Tobi/Bethkis), voriconazole (Vfend), select HIV agents (e.g., darunavir, delstrigo variants)
    • Oncology examples with PA: bosutinib (BOSULIF), brigatinib (ALUNBRIG entries indicate specialty/PA in adjacent rows), TAGRISSO (osimertinib) shows PA indicators in some rows
    • Limited Distribution examples are shown alongside PA (•) for select specialty drugs
    Prior Authorization

    Prior Authorization required for select antivirals

    Selected antivirals (including sofosbuvir-containing hepatitis C therapies) are commonly subject to prior authorization and may have quantity limits documented. Examples in the formulary include GENVOYA, HARVONI, SOVALDI, SOFOSBUVIR/VELPATASVIR, and EPCLUSA; many of these are also marked specialty and/or limited distribution.

    • GENVOYA — specialty and PA flagged in formulary entries
    • HARVONI, SOVALDI, EPCLUSA — PA dot present on many formulations; quantity limits are indicated on selected formulations
    • Sofosbuvir products often have both PA and Quantity Level Limits (QLL) entries
    Documentation Required

    Prior Authorization fields present

    PA fields are present across the formulary but not all entries include detailed PA criteria in this document. Presence of a PA flag indicates the operational requirement; providers should consult the payer's PA form or clinical criteria for the exact requirements.

    • The document shows the Prior Authorization column for each drug but does not reproduce full clinical PA criteria here
    • Where PA is indicated (•), follow payer PA form and guidance for documentation requirements
    • Some entries include Limited Distribution and Quantity Level Limit markers in the same row as PA
    Prior Authorization

    Prior authorization required for marked drugs

    Many drugs across therapeutic classes are marked for prior authorization; providers should submit PA requests for any product with the PA indicator to avoid coverage denial. Examples in the list include specialty antiretrovirals, antifungals, hepatitis C agents, and multiple oncology agents.

    • Submit PA for flagged drugs such as tobramycin nebulizer solutions, voriconazole, various HIV agents, and specialty oncology medications
    • Limited distribution products are often noted alongside PA and may restrict fulfillment to specific pharmacies
    Denial Risk

    Denial triggers

    Denial triggers: Claims may be denied for failure to obtain prior authorization, failure to meet step therapy requirements, or exceeding documented quantity level limits. The formulary notes these administrative controls and their potential impact on coverage.

    • No approved PA when required may lead to denial of coverage for that claim
    • Not attempting required step therapy (when a dot is present in the Step Therapy column) can be a basis for denial
    • Dispensing beyond state controlled‑substance limits can shift the cost to the member per state law
    Billing Rule

    Controlled substance dispensing limit

    Controlled substances: State dispensing limits may restrict covered quantities for controlled substances. If a pharmacy dispenses a controlled substance in excess of the applicable state limit, the member may be responsible for the full cost with no benefits applied.

    • Medication Synchronization and proration guidance do not override state controlled substance dispensing limits
    • Providers/pharmacies should confirm state dispensing limits before dispensing quantities that exceed typical limits
    Prior Authorization

    PA and quantity limits for sofosbuvir products

    PA and quantity limits for sofosbuvir products are documented in the formulary. Several sofosbuvir‑containing agents are marked with PA and Quantity Level Limits; absence of an approved PA or exceeding QLLs may result in claim denial or member financial responsibility.

    • SOVALDI and SOVALDI pellet/tab formulations show PA and QLL markers on certain rows
    • HARVONI entries indicate PA and may include quantity limits for specific presentations
    • Providers should submit PA requests and check QLLs when prescribing sofosbuvir‑containing regimens
    Note

    No explicit prior authorization or denial rules provided

    The document does not include explicit PA clinical criteria or step‑by‑step denial triggers for every listed drug within these chunks. Where PA/step therapy/QLL flags are blank, no explicit denial triggers are provided in this extract — consult the payer for product‑specific criteria.

    • Many formulary rows show PA/Step Therapy fields but lack the detailed rule text in this excerpt
    • Providers should not assume absence of a dot guarantees no UM program at the plan level — check specific plan materials
    Documentation Required

    Limited Distribution may affect fulfillment

    Limited Distribution: Some products are labeled Limited Distribution in the formulary, which may restrict which pharmacies can dispense them and affect fulfillment timelines. When Limited Distribution is indicated, providers and members may need to use a designated specialty pharmacy.

    • Limited Distribution flag is shown in the formulary alongside PA and Specialty indicators
    • Examples: APRETUDE, some hepatitis C and oncology agents, and select endocrine/specialty products
    Documentation Required

    Nonformulary exception submission

    Nonformulary exception submission: If a prescribed drug is not on the formulary, providers may submit a nonformulary consideration (formulary exception) request on behalf of the member. The P&T Committee reviews formulary status reconsiderations; requests concerning specific patients follow the dispute/appeal process.

    • Providers may complete a Formulary Status Reconsiderations form or write a supporting letter to the P&T Committee
    • Address for submission: Pharmacy Services, Capital Blue Cross P&T Committee, P.O. Box 773735, Harrisburg, PA 17177-3735
    Prior Authorization

    Submit Prior Authorization for flagged drugs

    Submit Prior Authorization for flagged drugs: The formulary highlights examples of products requiring PA; providers should use the payer's PA form or electronic process to submit supporting clinical documentation to secure approval prior to dispensing.

    • Examples of frequently PA‑flagged products: GENVOYA, HARVONI, SOVALDI, targeted oncology agents (TAGRISSO, TALZENNA), TRULICITY, selected glucagon/antidiabetic products
    • Retrovir (zidovudine) and other ARV entries show PA fields in the formulary — verify plan‑specific PA requirements
    Documentation Required

    Retrovir PA documentation

    Retrovir PA documentation: The formulary includes Retrovir (zidovudine) entries with PA fields present. Even for older agents, check the PA column and submit documentation when a PA is indicated to avoid processing delays or denials.

    • RETROVIR (zidovudine) cap and syrup entries are present in the formulary with PA column available
    • Use payer PA form if the Prior Authorization column indicates a requirement
    Documentation Required

    The document shows administrative attributes

    Administrative attributes: The formulary records multiple administrative attributes per product (Tier, Specialty, Prior Authorization, Step Therapy, Quantity Level Limits, PHC, Limited Distribution). Some entries indicate Quantity Level Limits or PHC status, but numeric limits or full clinical criteria are not reproduced in these chunks.

    • Required formulary fields visible: Drug Name, Tier, Specialty, Prior Authorization, Step Therapy, Quantity Level Limits, PHC, Limited Distribution
    • Some rows show Quantity Level Limits and PHC markers without numeric limits included in this excerpt
    Documentation Required

    Quantity/PHC documentation

    Quantity/PHC documentation: The formulary marks Quantity Level Limits (QLL) and Preventive Healthcare (PHC) where applicable. Numeric QLL values and clinical thresholds are not visible in these chunks — check plan materials for specifics.

    • Many product rows display a QLL marker (•) indicating limits apply; specific numeric limits are maintained in plan systems
    • PHC markers (for PPACA‑mandated preventive coverage) are displayed where applicable
    Step Therapy

    Step therapy indicated on drug list

    Step Therapy: A Step Therapy column is present and, when marked with a dot (•), indicates the plan may require trials of specified alternatives before covering the requested drug. Most entries in this extract show no step therapy indication; where present, providers must follow the plan's step sequence.

    • Step Therapy field is present for products but detailed sequence steps are not included in these chunks
    • Many formulary entries show no step therapy (mostly blank), but some specialty or oncology agents indicate step requirements

    Definitions and policy background

    Specialty drugs are prescription therapies used to treat complex or chronic conditions (for example, hepatitis, multiple sclerosis, and rheumatoid arthritis). They may be oral or injectable, are often self‑administered, and may require distribution through a participating specialty pharmacy (e.g., Accredo). Specialty products are commonly subject to utilization management such as Prior Authorization, Step Therapy, and Quantity Level Limits, and the plan typically limits specialty supplies to a 30‑day standard fill.

    Specialty drugs — definition and characteristics
    DefinitionDrugs used for complex conditions (examples: hepatitis, multiple sclerosis, rheumatoid arthritis); may be oral or injectable and can be self-administered.
    DistributionDistributed through the plan's specialty pharmacy provider, Accredo; some specialty drugs are only available via select pharmacies (Limited Distribution).
    Supply limitStandard specialty drug supply limit is 30-day per plan policy.
    Maintenance drugs — definition and retail supply notes
    DefinitionDrugs taken on an ongoing basis for chronic conditions such as high blood pressure, diabetes, or high cholesterol.
    Typical retail supplyMaintenance drugs may be eligible for a 30- or 90-day supply depending on the plan.
    Coverage noteMost prescription drug benefit plans provide coverage for up to a 30-day supply of drugs, with some exceptions for maintenance medications.
    Specialty flag — indicates specialty pharmacy requirement
    MeaningIndicates the drug is a specialty product that needs to be filled at a participating specialty pharmacy in the network.
    ActionMembers may be required to use the plan's specialty pharmacy (Accredo) for fulfillment; contact information provided in policy for service setup.
    Table columnShown in Column 3 (Specialty) of the drug list; specialty drugs may also be marked with a dot in the Specialty column.
    PHC (Preventive Healthcare drugs) definition
    DefinitionPHC (Preventive Healthcare) identifies drugs reviewed by the P&T Committee that are mandated by PPACA to have $0 cost share for eligible individual or non-grandfathered group plans.
    Table locationIndicated in Column 7 (PHC) of the drug list next to product entries.
    PurposeDenotes preventive healthcare drugs subject to specific cost-share rules under the Affordable Care Act.
    Limited Distribution definition
    DefinitionLimited Distribution indicates a restriction on which pharmacies can dispense the drug and limits where the member may obtain the prescription.
    ImplicationMembers may be required to use a specific pharmacy or specialty supplier for limited distribution drugs, potentially affecting fulfillment and requiring special sourcing.
    Table columnShown in Column 8 (Limited Distribution) of the drug list to identify restricted-distribution products.
    Prior Authorization flag (•) definition
    SymbolA bullet (•) in the Prior Authorization column indicates the drug requires prior authorization per the plan.
    Provider actionProvider must submit a prior authorization request and obtain approval before the drug will be covered when the PA indicator is present.
    Table locationPrior Authorization is one of the utilization management columns in the formulary table (Columns 4–6 include Prior Authorization, Step Therapy, Quantity Level Limits).
    Limited Distribution definition (alternate chunk)
    IndicatorLimited Distribution marks products that are dispensed through a restricted channel and may require a specific specialty or restricted supplier.
    Member impactMembers may be required to use an alternate pharmacy for limited distribution prescription drugs.
    Relation to specialtySome specialty drugs are also limited distribution; both attributes may appear in the formulary listing.
    Tier — formulary tier assignment definition
    DefinitionTier denotes the formulary tier assignment (e.g., GP = Generic Preferred, GN = Generic Nonpreferred, BP = Brand Preferred, SP = Specialty Preferred).
    Table placementTier is shown in Column 2 of the drug list and is used to determine benefit/cost-sharing level.
    ExamplesFormulary examples include BP, GN, GP and specialty designations noted alongside drug names in the listing.
    Limited Distribution (another reference)
    DefinitionLimited Distribution indicates the product is distributed through a limited network or specialty distributor and may show as a marker in the formulary.
    Effect on accessLimited Distribution entries may restrict where the member can fill the prescription and could require coordination with the specialty distributor.
    Appearance in listingLimited Distribution status may be shown as a bullet (•) or text marker in product rows across the formulary.
    Limited Distribution (additional references)
    MeaningLimited Distribution flags products that have constrained supply or distribution channels; the formulary may mark these with bullets to denote restricted access.
    Clinical implicationRestricted distribution can affect fulfillment timelines and may require routing to a designated dispensing location or vendor.
    DocumentationWhen Limited Distribution is indicated in the formulary, providers should consult plan resources for sourcing and dispensing instructions.
    Prior Authorization symbol definition
    SymbolThe Prior Authorization symbol (•) in the formulary indicates PA is required for that specific drug presentation.
    ConsequenceClaims for drugs flagged with PA may be denied without an approved prior authorization; obtain PA before dispensing when indicated.
    LocationPA indicators appear in the Prior Authorization column of the formulary drug table next to product entries.
    PHC flag noted in formulary
    PHC markerPHC flag appears in the formulary next to vaccine and other preventive products indicating preventive healthcare designation.
    Coverage impactDrugs marked PHC have been reviewed by the P&T Committee and may be subject to $0 cost share under PPACA for eligible members.
    Table columnPHC is displayed in Column 7 of the drug list; entries show PHC or are left blank if not applicable.
    Limited Distribution references across chunks
    DefinitionLimited Distribution indicates a supply/distribution restriction for specific products and may be shown as a marker in multiple formulary rows.
    Practical effectMay require use of designated pharmacies or specialty distributors and can limit member access via usual pharmacy channels.
    NotationLimited Distribution is recorded in the Limited Distribution column and is sometimes represented by bullets or text across entries.

    Step therapy applicability

    Summary
    Step therapy applies where noted in the formulary; products subject to step therapy are identified by a dot in the Step Therapy column of the drug list.
    Drug / ProductStep Therapy
    Formulary drug list — per‑drug Step Therapy column indicates applicability; if a dot is present the step therapy program applies to that product.
    Follow the plan's step therapy program as indicated in the Step Therapy column; refer to member-specific plan materials for program details.
    Example productsStep Therapy
    Multiple aminoglycoside and related entries (e.g., tobramycin nebulized solutions: Tobi/Bethkis) — Step Therapy = . (no step therapy documented for most presentations)
    Voriconazole (suspension and tablets) — Step Therapy = . (most listed rows show no step therapy)
    ProductStep Therapy note
    HARVONI (ledipasvir-sofosbuvir) pellet pack/tab — Step Therapy = . for most rows, but other UM flags (PA, QLL) present
    Lamivudine oral solution / lamivudine 100 mg (HBV) — select rows show Step Therapy = • indicating a step therapy marker for certain presentations
    ScopeObservation
    Vaccine and antiviral product lines include a Step Therapy field for each item but the majority of entries in these segments are blank (Step Therapy = .)
    Step Therapy field exists as an administrative column across many products but is largely unpopulated in these chunks
    Pediatric vaccineStep Therapy
    COVID-19 mRNA vaccine (Moderna) — pediatric 6 mo–11 yr presentations show Step Therapy = • in some rows (marker present) though no detailed step requirements are provided in these chunks.
    Product examplesStep Therapy
    Multiple oncology and specialty agents list a Step Therapy field; where a bullet (•) is shown the formulary indicates step therapy applies to that presentation.
    Bexarotene (Targretin) entries include Step Therapy markers in some rows (•) while many other product rows remain blank.
    Oncology / specialty productStep Therapy
    Sorafenib (Nexavar), sunitinib, and other oncology agents show Step Therapy flags in the formulary table (dots in Step Therapy column where present).
    TAFINLAR (dabrafenib) listings show Step Therapy markers (•) for certain presentations in these chunks.
    Antidiabetic / glucagon productStep Therapy
    GLYXAMBI — Step Therapy = • in at least one listed presentation (marker indicates step therapy applies).
    GVOKE (glucagon auto-injector) and related glucagon kit entries show Step Therapy markers on select rows (•) in the formulary extract.
    Member requirementImplication
    Where a bullet (•) appears in the Step Therapy column, the member must have met the applicable step therapy requirement before coverage is available.
    Formulary rows with Step Therapy = • should prompt prior verification of prior therapy alternatives per plan step therapy programs to avoid claim denials.
    Insulin productStep Therapy
    Most listed insulins (intermediate and basal examples such as HUMULIN N, NOVOLIN N, premixed products) show Step Therapy = . (blank) in these excerpts — step therapy is not documented for the majority of entries.
    A small number of insulin presentations include step therapy markers where specifically noted; otherwise Step Therapy fields are generally empty.

    Quantity level limits and related flags

    Specialty drugs — standard supply limit for specialty drugs (30-day)
    Specialty supply limitSpecialty drugs are limited to a 30-day supply per plan policy.
    Quantity Level Limits columnThe formulary includes a Quantity Level Limits column to denote QLLs (marked with a dot when applicable); numeric limits are not provided in all entries.
    Implication for dispensingIf a provider prescribes greater quantities than the QLL, the member may be responsible for costs beyond coverage limits.
    Example product (tobramycin nebu soln) — Quantity Level Limits column exists though numeric limits not present
    Product exampleTobramycin nebulized solution (Tobi/Bethkis) is listed in the formulary with a Quantity Level Limits column present, though numeric limits are not shown in these chunks.
    QLL markerEntries for tobramycin show Quantity Level Limits indicated (•) in some presentations.
    Related flagsTobramycin entries also display Specialty, Prior Authorization, and Limited Distribution markers in some rows.
    Products designated with Quantity Level Limits (bulleted or blank markers)
    DesignationMany products in the formulary are designated with Quantity Level Limits markers (bullets) or blank markers where QLL applies or is unspecified.
    ExamplesEntries across antimicrobial and antiviral classes show QLL markers in the Quantity Level Limits column for certain presentations.
    DocumentationSpecific numeric QLL values are not consistently provided in the visible chunks; the column indicates where limits apply.
    LAGEVRIO (molnupiravir) and select antiviral packs — QL indicated as bullet in some entries
    ExamplesLAGEVRIO (molnupiravir) and select antiviral packs are shown with Quantity Level Limits indicated (•) for some entries.
    QLL presenceSome antiviral presentations include a bullet in the Quantity Level Limits column to denote quantity restrictions (e.g., course limits).
    Related UM flagsAntiviral entries may also show PHC or other UM markers alongside QLL indicators.
    SOFOSBUVIR/VELPATASVIR and SOVALDI — Quantity Level Limits indicated
    ExamplesSOFOSBUVIR/VELPATASVIR (Epclusa) and SOVALDI (sofosbuvir) entries show Quantity Level Limits indicated (•) in some formulary rows.
    UM interplayThese hepatitis C antivirals are also frequently marked with Prior Authorization and Specialty indicators in the listing.
    Provider implicationAbsence of required PA or exceeding QLL for these agents may lead to denial or member financial responsibility.
    RECOMBIVAX HB — QL reference
    ProductRECOMBIVAX HB (hepatitis B vaccine, recombinant) is listed in the formulary with Quantity Level Limits PHC noted and Limited Distribution marked in at least one entry.
    Table presenceQLL PHC markers appear next to vaccine entries, though exact numeric QLLs are not shown in these chunks.
    ImplicationWhen QLL or Limited Distribution apply to vaccines, consult the formulary row for coverage attributes before dispensing.
    Pediatric COVID-19 mRNA vaccine entry shows Quantity Level Limits marker
    ExamplePediatric COVID-19 mRNA vaccine (Moderna, 6 mo–11 yr, 25 mcg/0.25 ml) is shown with a Quantity Level Limits PHC marker in the formulary listing.
    Table noteQLL and PHC markers are used for vaccine entries to indicate preventive status and any quantity restrictions.
    ActionRefer to the formulary row for specifics when administering pediatric vaccine presentations noted with QLL markers.
    Many specialty oncology agents have Quantity Level Limits indicated
    ScopeMany specialty oncology agents (examples: BOSULIF, CAPRELSA, COMETRIQ, COTELLIC) are indicated with Quantity Level Limits markers (•) in the formulary.
    Frequent pairingOncology agents with QLLs often also show Specialty and Prior Authorization indicators in the listing.
    Numeric limitsSpecific numeric QLLs for oncology agents are not provided in these chunks; the column denotes where limits apply.
    Quantity Level Limits column present across many drug listings (numeric limits not provided in chunks)
    Table existenceA Quantity Level Limits column is present across many drug listings to indicate where quantity restrictions apply, though numeric limits are not consistently listed in the visible chunks.
    InterpretationA bullet (•) in the QLL column denotes a quantity restriction for that drug presentation; absence of a numeric value in the chunk means consult full formulary for details.
    Provider noteWhen QLL is indicated, providers should verify numeric limits and apply prior authorization or exception processes as needed.
    SOLIQUA 100/33 — Quantity Level Limits indicated
    ProductSOLIQUA 100/33 (insulin glargine–lixisenatide) is listed with a Quantity Level Limits marker (•) in the formulary entries shown.
    ImplicationQLL indicates quantity restrictions apply to specific pack or pen presentations; check formulary details before dispensing.
    Associated flagsSOLIQUA rows may also include Tier and Limited Distribution attributes in the table.
    BAQSIMI TWO PACK / GVOKE KIT — Quantity Level Limits indicated for some pack configurations
    ProductsBAQSIMI Two Pack and GVOKE Kit entries show Quantity Level Limits indicated for some pack configurations in the formulary.
    QLL specificsSome emergency glucagon pack configurations are noted with QLL markers (•) for certain pack sizes; numeric limits are not shown in these chunks.
    Provider actionConfirm QLL and PA requirements for glucagon products prior to dispensing larger pack sizes.
    Various listed products show Quantity Level Limits markers
    ScopeVarious diabetes-related and glucagon products display Quantity Level Limits markers (•) in the formulary indicating quantity restrictions for certain presentations.
    ExamplesEntries include GLYXAMBI, JANUMET, TRULICITY, FIASP, ZEGALOGUE and others with QLL indicators for specific strengths or pack sizes.
    ActionCheck the formulary row for exact QLL values and processing requirements when dispensing these products.
    NOVOLIN N RELION — Quantity Level Limits unspecified or marked
    ProductNOVOLIN N (Relion) is listed with Quantity Level Limits sometimes marked (•) or unspecified in the formulary rows shown.
    PHC noteNOVOLIN N Relion entries also show PHC markers in some lines alongside QLL indicators.
    InterpretationWhen QLL is unspecified in the chunk, consult the full formulary or payer resources for numeric limits before dispensing.

    Specialty pharmacy and site of service rules

    Billing Rule

    Check site-of-care and billing for limited distribution/infusion drugs

    Limited distribution specialty drugs may require site-specific coverage or billing under the medical benefit (for non–self-administered injectables); providers should verify site-of-care billing rules and coordinate with the specialty pharmacy.

    • Contact Accredo for specialty distribution and billing instructions
    • Verify whether a drug is billed under prescription or medical benefit
    Billing Rule

    Fill specialty drugs at participating specialty pharmacies

    Specialty drugs indicated in the formulary must be filled at participating specialty pharmacies in the network; providers and members may be directed to use Accredo for specialty dispensing.

    • Accredo is the plan's designated specialty pharmacy
    • Call 833.721.1626 or fax 888.302.1028 for service setup